Bcar1/p130Cas protein and primary breast cancer: Prognosis and response to tamoxifen treatment

Journal of the National Cancer Institute

Volumn 92, Issue 2, 2000, Pages 120-127

  Van Der Flier, Silvia ^b   Brinkman, Arend ^b   Look, Maxime P ^b   Kok, Elisabath M ^b   Meijer van Gelder, Marion E ^b   Klijn, Jan G M ^b   Dorssers, Lambert C J ^a   Foekens, John A ^b  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P130; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0034684987     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.2.120     Document Type: Article

References (49)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83: 835-9.
2. Freedman LP. Increasing the complexity of coactivation in nuclear receptor signaling. Cell 1999;97:5-8.
3. Kuiper GG, Enmark E, Pelto-Hu kko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sei USA 1996;93:5925-30.
4. Mosselman S, Polman J, Dijkema R. ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392:49-53.
5. Katzenellenbogen BS, Korach KS. A new actor in the estrogen receptor drama - enter ER-β. Endocrinology 1997;138:861-2.
6. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351: 1451-67.
7. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 1977;39:1289-94.
8. Horwitz KB. Mechanisms of hormone resistance in breast cancer. Breast Cancer Res Treat 1993;26:119-30.
9. Chan CM, Dowsett M. A novel estrogen receptor variant mRNA lacking exons 4 to 6 in breast carcinoma. J Steroid Biochem Mol Biol 1997;62: 419-30.
10. Dowsett M, Daffada A, Chan CM, Johnston SR. Oestrogen receptor mutants and variants in breast cancer. Eur J Cancer 1997;33:1177-83.
11. Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 1991;83:1477-82.
12. Johnston SR, Haynes BP, Smith IE, Jarman M, Sacks NP, Ebbs SR, et al. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet 1993;342:1521-2.
13. Dorssers LC, Van Agthoven T, Dekker A, Van Agthoven TL, Kok EM. Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bcar-1, a common integration site. Mol Endocrinol 1993;7:870-8.
14. Dorssers LC, Veldscholte J. Identification of a novel breast-cancer-anti-estrogen-resistance (BCAR2) locus by cell-fusion-mediated gene transfer in human breast-cancer cells. Int J Cancer 1997;72:700-5.
15. Van Agthoven T, Van Agthoven TL, Dekker A, Van der Spek PJ. Vreede L, Dorssers LC. Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 1998;17:2799-808.
16. Brinkman A, van der Flier, Kok EM, Dorssers LC. BCAR1, a human homologue of the adapter protein p130Cas and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 2000;92:000-000]
17. Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Mano H, et al. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J 1994; 13:3748-56.
18. Cas to SH2 and SH3 domains of Src kinase. J Biol Chem 1996;271:8959-65.
19. cas signaling complex formation upon integri i-mediated cell adhesion: a role for Src family kinases. Mol Cell Biol 1996;16:2606-13.
20. Cas) are elevated in cytoskeleton-associated fractions following adhesion and Src transformation-requirements for Src kinase activity and FAK proline-rich motifs. J Biol Chem 1997;272: 5501-9.
21. Cas as a mediator of focal adhesion kinase-promoted cell migration. J Cell Biol 1998;140:211-21.
22. Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh DA. CAS/Crk coupling serves as a "molecular switch" for induction of cell migration. J Cell Biol 1998;140:961-72.
23. Tamura M, Gu J, Takino T, Yamada KM. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res 1999;59:442-9.
24. Cas. Involvement of phosphatidylinositol 3′-kinase and actin cytoskeleton. J Biol Chem 1997;272:25993-8.
25. Ingham RJ, Krebs DL, Barbazuk SM, Turck CW, Hirai H, Matsuda M, et al. B cell antigen receptor signaling induces the formation of complexes containing the Crk adapter proteins. J Biol Chem 1996;271: 32306-14.
26. Cas as a substrate of Yersinia YopH (Yop51), a bacterial protein tyrosine phosphatase that translocates into mammalian cells and targets focal adhesions. EMBO J 1997;16: 2730-44.
27. Cas and FAK, and the associated accumulation of these proteins in peripheral focal adhesions. EMBO J 1997;16:2307-18.
28. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WL, Klijn JG. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 1999;79:300-7.
29. Sherman CD, Hossfeld DK. Breast cancer. In: Hossfeld DK, Sherman CD, Lover RR, Bosch FX. editors. Manual of clinical oncology. Geneva (Switzerland): International Union Against Cancer; 1990. p. 253-71.
30. Nicholson S, Sainsbury JR, Halcrow P, Chambers P, Farndon JR, Harris AL. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1989; 1:182-5.
31. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metaslatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992;10:1284-91.
32. Foekens JA, Look MP, Peters HA, Van Putten WL, Portengen H, Klijn JG. Urokinase-type plasminogen activator and its inhibitor PAI-1 : predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995;87:751-6.
33. Foekens JA, Portengen H, Look MP, Van Putten WL, Thirion B, Bontenbal M, et al. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 1994;70:1217-23.
34. Robertson JF, Willsher PC, Cheung KL, Blarney RW. The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 1997;33:1774-9.
35. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March. 1979. in the Netherlands Cancer Institute. Eur J Cancer 1980;16:1513-5.
36. Foekens JA, Portengen H, Van Putten WL, Peters HA, Krijnen HL, Alexieva-Figusch J, et al. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 1989;49:5823-8.
37. Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985;4:87-90.
38. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-81.
39. Horowitz KB, McGuire WL. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975;189:726-7.
40. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995;13:513-29.
41. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 1993;26:237-46.
42. Lykkesfeldt AE, Larsen SS, Briand P. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 1995;61:529-34.
43. Larsen SS, Madsen MW, Jensen BL, Lykkesfeldt AE. Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness. Int J Cancer 1997;72:1129-36.
44. cas and Nek adaptor proteins. Mol Cell Biol 1997;17:1702-13.
45. Schlaepfer DD, Jones KC, Hunter T. Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2 mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phos-phorylation events. Mol Cell Biol 1998;18:2571-85.
46. Burnham MR, Harte MT, Richardson A, Parsons JT, Bouton AH. The identification of p130cas-binding proteins and their role in cellular transformation. Oncogene 1996; 12:2467-72.
47. Astier A, Avraham H, Manie SN, Groopman J, Canty T, Avraham S, et al. The related adhesion focal tyrosine kinase is tyrosine-phosphorylated after β1-integrin stimulation in B cells and binds to p130cas. J Biol Chem 1997;272:228-32.
48. Garton AJ, Burnham MR, Bouton AH, Tonks NK. Association of PTP-PEST with the SH3 domain of p130cas; a novel mechanism of protein tyrosine phosphatase substrate recognition. Oncogene 1997;15:877-85.
49. Ohba T, Ishino M, Aoto H, Sasaki T. Interaction of to proline-rich sequences of cell adhesion kinase β with SH3 domains of p130Cas-related proteins and a GTPase-activating protein, Graf. Biochem J 1998;330: 1249-54.